Depomed (DEPO) Shares are Up 11.6%

Depomed (DEPO) : Traders are bullish on Depomed (DEPO) as it has outperformed the S&P 500 by a wide margin of 10.05% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.12%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.6% in the last 1 week, and is up 12.79% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Depomed (NASDAQ:DEPO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.51 and $20.49 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $21.29. The buying momentum continued till the end and the stock did not give up its gains. It closed at $21.17, notching a gain of 4.13% for the day. The total traded volume was 1,602,434 . The stock had closed at $20.33 on the previous day.

The stock has recorded a 20-day Moving Average of 10.78% and the 50-Day Moving Average is 8.31%. Depomed, Inc. is up 36.49% in the last 3-month period. Year-to-Date the stock performance stands at 16.77%.

Depomed (DEPO) : The most positive equity analysts on Depomed (DEPO) expects the shares to touch $36, whereas, the least positive believes that the stock will trade at $14 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $23.82 with an expected fluctuation of $5.71 from the mean.


Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.